231 related articles for article (PubMed ID: 33520368)
1. Tumor-intrinsic and -extrinsic (immune) gene signatures robustly predict overall survival and treatment response in high grade serous ovarian cancer patients.
Mysona DP; Tran L; Bai S; Dos Santos B; Ghamande S; Chan J; She JX
Am J Cancer Res; 2021; 11(1):181-199. PubMed ID: 33520368
[TBL] [Abstract][Full Text] [Related]
2. Prognostic gene expression signature for high-grade serous ovarian cancer.
Millstein J; Budden T; Goode EL; Anglesio MS; Talhouk A; Intermaggio MP; Leong HS; Chen S; Elatre W; Gilks B; Nazeran T; Volchek M; Bentley RC; Wang C; Chiu DS; Kommoss S; Leung SCY; Senz J; Lum A; Chow V; Sudderuddin H; Mackenzie R; George J; ; Fereday S; Hendley J; Traficante N; Steed H; Koziak JM; Köbel M; McNeish IA; Goranova T; Ennis D; Macintyre G; Silva De Silva D; Ramón Y Cajal T; García-Donas J; Hernando Polo S; Rodriguez GC; Cushing-Haugen KL; Harris HR; Greene CS; Zelaya RA; Behrens S; Fortner RT; Sinn P; Herpel E; Lester J; Lubiński J; Oszurek O; Tołoczko A; Cybulski C; Menkiszak J; Pearce CL; Pike MC; Tseng C; Alsop J; Rhenius V; Song H; Jimenez-Linan M; Piskorz AM; Gentry-Maharaj A; Karpinskyj C; Widschwendter M; Singh N; Kennedy CJ; Sharma R; Harnett PR; Gao B; Johnatty SE; Sayer R; Boros J; Winham SJ; Keeney GL; Kaufmann SH; Larson MC; Luk H; Hernandez BY; Thompson PJ; Wilkens LR; Carney ME; Trabert B; Lissowska J; Brinton L; Sherman ME; Bodelon C; Hinsley S; Lewsley LA; Glasspool R; Banerjee SN; Stronach EA; Haluska P; Ray-Coquard I; Mahner S; Winterhoff B; Slamon D; Levine DA; Kelemen LE; Benitez J; Chang-Claude J; Gronwald J; Wu AH; Menon U; Goodman MT; Schildkraut JM; Wentzensen N; Brown R; Berchuck A; Chenevix-Trench G; deFazio A; Gayther SA; García MJ; Henderson MJ; Rossing MA; Beeghly-Fadiel A; Fasching PA; Orsulic S; Karlan BY; Konecny GE; Huntsman DG; Bowtell DD; Brenton JD; Doherty JA; Pharoah PDP; Ramus SJ
Ann Oncol; 2020 Sep; 31(9):1240-1250. PubMed ID: 32473302
[TBL] [Abstract][Full Text] [Related]
3. A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment.
Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q
Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023
[TBL] [Abstract][Full Text] [Related]
4. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer.
Hillman RT; Chisholm GB; Lu KH; Futreal PA
J Natl Cancer Inst; 2018 Mar; 110(3):265-72. PubMed ID: 29584920
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients.
Buttarelli M; Ciucci A; Palluzzi F; Raspaglio G; Marchetti C; Perrone E; Minucci A; Giacò L; Fagotti A; Scambia G; Gallo D
J Exp Clin Cancer Res; 2022 Feb; 41(1):50. PubMed ID: 35120576
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma.
Yuan D; Zhu H; Wang T; Zhang Y; Zheng X; Qu Y
Eur J Med Res; 2023 Oct; 28(1):465. PubMed ID: 37884970
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
Zhang Y; Liu J; Raj-Kumar PK; Sturtz LA; Praveen-Kumar A; Yang HH; Lee MP; Fantacone-Campbell JL; Hooke JA; Kovatich AJ; Shriver CD; Hu H
Breast Cancer Res Treat; 2020 Dec; 184(3):689-698. PubMed ID: 32880016
[TBL] [Abstract][Full Text] [Related]
8. Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies.
Wu Q; Tian R; He X; Liu J; Ou C; Li Y; Fu X
Front Immunol; 2023; 14():1164408. PubMed ID: 37090728
[TBL] [Abstract][Full Text] [Related]
9. A Robust Gene Expression Prognostic Signature for Overall Survival in High-Grade Serous Ovarian Cancer.
Zhao Y; Yang SM; Jin YL; Xiong GW; Wang P; Snijders AM; Mao JH; Zhang XW; Hang B
J Oncol; 2019; 2019():3614207. PubMed ID: 31885574
[TBL] [Abstract][Full Text] [Related]
10. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Omics Data Reveals Nucleotide Excision Repair-Related Genes Signature in Highly-Grade Serous Ovarian Cancer to Predict Prognosis.
Dai D; Li Q; Zhou P; Huang J; Zhuang H; Wu H; Chen B
Front Cell Dev Biol; 2022; 10():874588. PubMed ID: 35769257
[TBL] [Abstract][Full Text] [Related]
12. Development of a Novel Autophagy-related Prognostic Signature for Serous Ovarian Cancer.
An Y; Bi F; You Y; Liu X; Yang Q
J Cancer; 2018; 9(21):4058-4071. PubMed ID: 30410611
[No Abstract] [Full Text] [Related]
13. Development and Validation of an Immune-Related Gene-Pair Model of High-Grade Serous Ovarian Cancer After Platinum-Based Chemotherapy.
Lin J; Xu X; Sun D; Li T
Front Oncol; 2020; 10():626555. PubMed ID: 33680950
[TBL] [Abstract][Full Text] [Related]
14. A multimodal radiomic machine learning approach to predict the LCK expression and clinical prognosis in high-grade serous ovarian cancer.
Zhan F; He L; Yu Y; Chen Q; Guo Y; Wang L
Sci Rep; 2023 Sep; 13(1):16397. PubMed ID: 37773310
[TBL] [Abstract][Full Text] [Related]
15. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
16. RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers.
Jones WD; Michener CM; Biscotti C; Braicu I; Sehouli J; Ganapathi MK; Ganapathi RN
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32156016
[TBL] [Abstract][Full Text] [Related]
17. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
18. Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response.
Mairinger F; Bankfalvi A; Schmid KW; Mairinger E; Mach P; Walter RF; Borchert S; Kasimir-Bauer S; Kimmig R; Buderath P
Cancer Manag Res; 2019; 11():9571-9583. PubMed ID: 31814759
[TBL] [Abstract][Full Text] [Related]
19. Construction of an aging-related risk signature in high-grade serous ovarian cancer for predicting survival outcome and immunogenicity.
Liu S; Liu Y; Ma J; Lv R; Wang F
Medicine (Baltimore); 2023 Sep; 102(35):e34851. PubMed ID: 37657028
[TBL] [Abstract][Full Text] [Related]
20. An immune-related gene pairs signature predicts overall survival in serous ovarian carcinoma.
Zhang L; Zhu P; Tong Y; Wang Y; Ma H; Xia X; Zhou Y; Zhang X; Gao F; Shu P
Onco Targets Ther; 2019; 12():7005-7014. PubMed ID: 31695415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
